SPHK1 and prostate carcinoma: Although SphK1 inhibitors have been successful in increasing chemosensitivity [29, 65, 66], there are examples demonstrating discriminatory chemosensitivity depending on the expression of the two major SphK1 isoforms in hormone-dependent and independent prostate cancer cell lines [35, 36].